Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature

Condition(s) studied

Investigational drug(s) / intervention(s)

No Interventions: no intervention

Study summary

MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.

With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.

Yet, so far, these complications have only been documented in a few single case reports.

Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.

Eligibility

Primary outcome measure(s)

• Type of neuromuscular complications — up to 8 years

Trial sites (1)

More Central Hospital, Nancy, France trials in France

Other trials for the same condition